Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

BCAX Bicara Therapeutics

交易中 08-10 11:37:14 EDT

28.07

+0.01

+0.04%

最高28.40	最低27.07	成交量19.31万
今开27.83	昨收28.06	日振幅4.75%
总市值18.38亿	流通市值14.54亿	总股本6,547万
成交额541.01万	换手率0.37%	流通股本5,181万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"BCAX","market":"US","secType":"STK","nameCN":"Bicara Therapeutics","latestPrice":28.07,"timestamp":1786376228634,"preClose":28.06,"halted":0,"volume":193080,"delay":0,"changeRate":0.00035637918745550835,"floatShares":51807590,"shares":65467200,"eps":-2.797107,"marketStatus":"交易中","change":0.01,"latestTime":"08-10 11:37:14 EDT","open":27.83,"high":28.4,"low":27.0676,"amount":5410070.7072,"amplitude":0.047484,"askPrice":28.08,"askSize":271,"bidPrice":28.04,"bidSize":22,"shortable":3,"etf":0,"ttmEps":-2.797107,"tradingStatus":2,"nextMarketStatus":{"tag":"盘后交易","tradingStatus":3,"beginTime":1786392000000},"marketStatusCode":2,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":28.06,"preHourTrading":{"tag":"盘前","latestPrice":28.09,"preClose":28.06,"latestTime":"08:57 EDT","volume":483,"amount":13435.94427,"timestamp":1786366674825,"change":0.03,"changeRate":0.001069,"amplitude":0.038685},"postHourTrading":{"tag":"盘后","latestPrice":28.06,"preClose":28.06,"latestTime":"19:34 EDT","volume":4114,"amount":115442.64,"timestamp":1786145647724,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.889472,"impliedVol":0.552,"impliedVolPercentile":0.7968},"requestUrl":"/m/hq/s/BCAX","defaultTab":"news","newsList":[{"id":"1150998880","title":"Bicara Therapeutics公布1B期研究结果：展现深度、持久的应答与良好的耐受性安全性特征","url":"https://stock-news.laohu8.com/highlight/detail?id=1150998880","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1150998880?lang=zh_cn&edition=full","pubTime":"2026-05-22 05:09","pubTimestamp":1779397753,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc 公布的最新1B期临床研究数据揭示，其试验性疗法展现出深度且持久的治疗应答，同时具备耐受性良好的安全性特征。该研究结果进一步支持了该疗法的临床开发潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1111684845","title":"异动解读 | 启动关键性试验第三阶段，Bicara Therapeutics盘中大涨5.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=1111684845","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1111684845?lang=zh_cn&edition=full","pubTime":"2026-03-30 22:15","pubTimestamp":1774880121,"startTime":"0","endTime":"0","summary":"消息面上，公司已正式启动其核心候选药物Fortifi-Hn01的关键性试验第三阶段。该阶段标志着药物研发进程中的重要里程碑，旨在进一步评估其在头颈癌治疗中的有效性与安全性，这一积极进展显著增强了投资者对公司研发前景的信心。Fortifi-Hn01作为Bicara Therapeutics研发管线中的重点产品，其第三阶段临床试验的推进备受业界关注，若最终结果符合预期，该药物有望为头颈癌患者提供新的治疗选择，并可能为公司带来重要的商业机会。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154155522","title":"异动解读 | Bicara Therapeutics启动关键性试验第三阶段，股价盘前大涨5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=1154155522","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1154155522?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:36","pubTimestamp":1774870598,"startTime":"0","endTime":"0","summary":"消息面上，公司已正式启动其核心候选药物Fortifi-Hn01的关键性试验第三阶段。该阶段标志着药物研发进程中的重要里程碑，旨在进一步评估其在头颈癌治疗中的有效性与安全性，这一积极进展显著增强了投资者对公司研发前景的信心。Fortifi-Hn01作为Bicara Therapeutics研发管线中的重点产品，其第三阶段临床试验的推进备受业界关注，若最终结果符合预期，该药物有望为头颈癌患者提供新的治疗选择，并可能为公司带来重要的商业机会。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1178506877","title":"Bicara Therapeutics启动Fortifi-Hn01关键性试验第三阶段 中期分析预计2027年中进行","url":"https://stock-news.laohu8.com/highlight/detail?id=1178506877","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1178506877?lang=zh_cn&edition=full","pubTime":"2026-03-30 19:35","pubTimestamp":1774870518,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics（股票代码：BCAX）已正式启动其核心候选药物Fortifi-Hn01的关键性试验第三阶段。该阶段标志着药物研发进程中的重要里程碑，旨在进一步评估其在头颈癌治疗中的有效性与安全性。\n根据公司公布的时间表，该项试验的中期分析预计将于2027年中期完成。这一关键节点将为后续临床决策提供重要数据支持，并可能影响该疗法的最终审批路径。\nFortifi-Hn01作为Bicara Therapeutics研发管线中的重点产品，其第三阶段临床试验的推进备受业界关注。若最终结果符合预期，该药物有望为头颈癌患者提供新的治疗选择。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162640845","title":"Bicara Therapeutics超额认购公开发行圆满收官，承销商全额行使额外购股权","url":"https://stock-news.laohu8.com/highlight/detail?id=1162640845","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1162640845?lang=zh_cn&edition=full","pubTime":"2026-02-27 05:30","pubTimestamp":1772141409,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics宣布其公开发行已正式完成，本次发行获得超额认购。承销商已全额行使购买额外股份的选择权。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134029809","title":"Bicara Therapeutics宣布1.5亿美元普通股及预付认股权证公开发行定价","url":"https://stock-news.laohu8.com/highlight/detail?id=1134029809","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1134029809?lang=zh_cn&edition=full","pubTime":"2026-02-25 12:13","pubTimestamp":1771992810,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics已正式确定其1.5亿美元普通股及预付认股权证的公开发行价格。此次融资将支持公司推进其肿瘤治疗产品管线的临床开发。市场密切关注此次发行对公司未来发展的影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCAX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1132051680","title":"Ficerafusp Alfa 2000毫克Q2w方案在1L R/M HPV阴性头颈鳞癌中展现深度持久疗效 并支持开发更低频给药方案","url":"https://stock-news.laohu8.com/highlight/detail?id=1132051680","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1132051680?lang=zh_cn&edition=full","pubTime":"2026-02-20 05:33","pubTimestamp":1771536793,"startTime":"0","endTime":"0","summary":"Ficerafusp Alfa采用2000毫克每两周给药方案，在治疗一线复发/转移性HPV阴性头颈部鳞状细胞癌患者时，展现出深度且持久的肿瘤缓解效果。该积极数据为进一步开发给药频率更低的治疗方案提供了有力支持。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109954715","title":"Bicara Therapeutics计划开发Ficerafusp Alfa的负荷剂量与三周一次维持方案，待监管审批","url":"https://stock-news.laohu8.com/highlight/detail?id=1109954715","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1109954715?lang=zh_cn&edition=full","pubTime":"2026-02-20 05:33","pubTimestamp":1771536792,"startTime":"0","endTime":"0","summary":"Bicara Therapeutics Inc. 宣布，公司计划为其在研药物Ficerafusp Alfa开发一种负荷剂量联合每三周一次维持给药的用药方案。该开发计划的推进，将取决于与监管机构达成一致意见。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCAX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2484130309","title":"Bicara Therapeutics Inc.2024财年第三财季实现净利润-17.48百万美元，同比增加23.50%","url":"https://stock-news.laohu8.com/highlight/detail?id=2484130309","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2484130309?lang=zh_cn&edition=full","pubTime":"2024-11-19 18:00","pubTimestamp":1732010416,"startTime":"0","endTime":"0","summary":"11月19日，Bicara Therapeutics Inc.公布财报，公告显示公司2024财年第三财季净利润为-17.48百万美元，同比增加23.50%；其中营业收入为0.00美元，每股基本收益为-0.32美元。机构评级：截至2024年11月19日，当前有4家机构对Bicara Therapeutics Inc.目标价做出预测，其中目标均价为42.05美元，其中最低目标价为36.00美元，最高目标价为48.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119180024abcede94&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BCAX","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157360442","title":"异动解读 | TPG支持的生物科技公司Bicara Therapeutics首次公开募股(IPO)大涨45.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=1157360442","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1157360442?lang=zh_cn&edition=full","pubTime":"2024-09-14 01:16","pubTimestamp":1726247788,"startTime":"0","endTime":"0","summary":"9月13日,由风险投资巨头TPG支持的生物科技公司Bicara Therapeutics Inc在纳斯达克上市首日,股价大涨45.8%,引发投资者热捧。Bicara Therapeutics是一家专注于开发创新癌症疗法的生物科技公司。在本次IPO中,公司共发行了1320万股股票,融资2.25亿美元,超出了原计划规模。数据显示,今年美国的IPO市场复苏迹象明显,其中以医疗健康板块为重点领域。有分析认为,Bicara Therapeutics超额认购的成功上市预示着资金青睐具有前景的生物科技创新项目,为行业发展带来了新的契机。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["BCAX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bicara.com","stockEarnings":[{"period":"1week","weight":0.0354},{"period":"1month","weight":-0.0321},{"period":"3month","weight":0.2427},{"period":"6month","weight":0.8268},{"period":"1year","weight":1.751},{"period":"ytd","weight":0.6673}],"compareEarnings":[{"period":"1week","weight":0.0351},{"period":"1month","weight":0.0374},{"period":"3month","weight":0.0483},{"period":"6month","weight":0.1197},{"period":"1year","weight":0.223},{"period":"ytd","weight":0.1339}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Bicara Therapeutics Inc.于2018年12月12日根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司，专注于为实体瘤开发双功能疗法。其主要候选药物ficerafusp alfa同时靶向EGFR和TGF-β通路，目前正在针对头颈部鳞状细胞癌进行一项关键性试验。","exchange":"NASDAQ","name":"Bicara Therapeutics","nameEN":"Bicara Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"Bicara Therapeutics,BCAX,Bicara Therapeutics股票,Bicara Therapeutics股票老虎,Bicara Therapeutics股票老虎国际,Bicara Therapeutics行情,Bicara Therapeutics股票行情,Bicara Therapeutics股价,Bicara Therapeutics股市,Bicara Therapeutics股票价格,Bicara Therapeutics股票交易,Bicara Therapeutics股票购买,Bicara Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Bicara Therapeutics(BCAX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供Bicara Therapeutics(BCAX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}